Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncolys BioPharmaTSE:4588 -6.00%40 PS Ratio is 1,873.31 as of Jul. 21, 2026, which is 4120% above its 10-year median of 44.39. GuruFocus rates TSE:4588 with a GF Score™ of 40/100 and a GF Value™ of 円361.77 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, Oncolys BioPharma ranks worse than 97.31% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Oncolys BioPharma's share price is 円2351.00.
Oncolys BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was 円1.26. Hence, Oncolys BioPharma's PS Ratio for today is 1,873.31.
The historical rank and industry rank for Oncolys BioPharma's PS Ratio or its related term are showing as below:
TSE:4588'
s PS Ratio Range Over the Past 10 Years
Min: 7.41 Med: 44.39 Max: 2741.51
Current: 1873.31
During the past 13 years, Oncolys BioPharma's highest PS Ratio was 2741.51. The lowest was 7.41. And the median was 44.39.
TSE:4588's PS Ratio is ranked worse than 97.31% of 930
companies
in the Biotechnology industry
Industry Median: 9.3
vs TSE:4588: 1873.31
Oncolys BioPharma Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Oncolys BioPharma was -22.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -73.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -54.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -21.40% per year.
During the past 13 years, Oncolys BioPharma's highest 3-Year average Revenue per Share Growth Rate was 380.10% per year. The lowest was -73.00% per year. And the median was -0.70% per year.
Back to Basics: PS Ratio
Oncolys BioPharma (TSE:4588) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Oncolys BioPharma PS Ratio Related Terms
Oncolys BioPharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Oncolys BioPharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oncolys BioPharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncolys BioPharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Oncolys BioPharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Oncolys BioPharma's Share Price of today is 円2351.00. Oncolys BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Oncolys BioPharma (TSE:4588) has a PS Ratio of 1,873.31 as of Jul. 21, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Oncolys BioPharma and its competitors. This is 4120% above median its historical median of 44.39. Over the past decade, Oncolys BioPharma's PS Ratio has ranged from 7.41 to 2,741.51. According to the industry distribution chart, Oncolys BioPharma ranks #905 out of 930 companies in the Biotechnology industry, placing it in the top 97.3%.
Is Oncolys BioPharma's PS Ratio too high?
Oncolys BioPharma's current PS Ratio of 1,873.31 is 4120% above median its 10-year median of 44.39. Over the past 10 years, this metric has ranged from a low of 7.41 to a high of 2,741.51. The Biotechnology industry median PS Ratio is 9.30. Oncolys BioPharma's value of 1,873.31 is 20043.1% above this industry median. Based on the distribution chart, Oncolys BioPharma ranks #905 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncolys BioPharma ranks #905 out of 930 companies for PS Ratio. This places Oncolys BioPharma in the lower half of its industry. The industry median PS Ratio is 9.30. Oncolys BioPharma's value of 1,873.31 is 20043.1% above this benchmark. Historically, Oncolys BioPharma's own PS Ratio has ranged from 7.41 to 2,741.51 over the past decade. While the company's 10-year median is 44.39 vs. the industry median of 9.30, Oncolys BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.30, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncolys BioPharma's current PS Ratio of 1,873.31 is 20043.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Oncolys BioPharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncolys BioPharma's current PS Ratio is 1,873.31, which is 4120% above median its own 10-year median of 44.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円361.77, compared to a current price of 円2,351.00 — trading 549.9% above its estimated fair value. The current PS Ratio is 1,873.31, which is 4120% above median its 10-year median of 44.39 and 20043.1% above the Biotechnology industry median of 9.30. Oncolys BioPharma's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current PS Ratio is 1,873.31 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?
Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued.
The current stock price of 円2,351.00 is trading 549.9% above its estimated GF Value™ of 円361.77.
GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.
Key valuation signals for TSE:4588:
PS Ratio: 1,873.31 (4120% above median its 10-year median of 44.39)
GF Value™: 円361.77 vs. price of 円2,351.00 (549.9% above fair value)
Industry Position: 20043.1% above the Biotechnology median (#905 of 930)
No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score
Get the complete analysis for TSE:4588
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4588 has been successfully added to your 
